Technologies and Systems for Assessing Human Energy Metabolism and Nutritional Rehabilitation
NCT ID: NCT07056504
Last Updated: 2025-09-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
80 participants
OBSERVATIONAL
2025-07-09
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary research question is:
How does energy metabolism change during the rehabilitation process in individuals recovering from traumatic brain injury, stroke, or major surgical procedures? To answer this, participants will undergo a comprehensive set of assessments, including measurements of height and weight, body composition, resting metabolic rate, physical activity levels, total energy expenditure, psychological health, food intake and hunger ratings, sleep quality, cognitive performance, non-invasive brain function monitoring, and gait analysis. Fecal and blood samples will also be collected for untargeted metabolomics analysis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Remote Intelligent Interactive Virtual Reality Assessment in Patients With Degenerative Lumbar Spine Diseases
NCT05425680
A Study of the Safety and Efficacy of Intelligent Powered Exoskeletons in Postoperative Spinal Rehabilitation
NCT06097000
Feasibility of the First Known Adaptive Intervention for People With SCI
NCT04726891
Effects of Ambulation Training Utilizing an Exoskeleton Robot on Subjects With Spinal Cord Injury
NCT03340792
Restoring Walking With a Powered Exoskeleton After Spinal Cord Injury
NCT02322125
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. Resting Energy Expenditure (REE) REE will be measured via indirect calorimetry using a respiratory hood system (Cosmed). Participants will report to the laboratory after an overnight fast, lie supine on a flat bed, and have the hood placed over their head. Oxygen consumption and carbon dioxide production will be recorded for 40 minutes, with the final 10 minutes used for analysis. The system will be quality-checked regularly using a turbine test, and monthly validation will be conducted via an alcohol combustion test.
3. Total Energy Expenditure (TEE)
TEE will be assessed using two complementary methods:
Doubly Labeled Water (DLW) Method: Urine samples from the DLW subset will be stored at -20 °C and shipped on dry ice to Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences. Isotope ratios will be analyzed using a Liquid Water Isotope Analyzer (ABB). CO₂ production will be calculated using the latest equation from Speakman et al. (2021, Cell Reports Medicine), and TEE will be estimated using the Weir equation.
Metabolic Chamber: TEE will also be measured using a whole-body metabolic chamber (Maastricht Instruments, Netherlands), which continuously tracks oxygen consumption and carbon dioxide production. Participants will remain in the chamber for 48 hours, engaging in routine daily activities. Data from the second day will be analyzed to estimate TEE.
4. Physical Activity Physical activity will be assessed using a GT3X accelerometer worn on the hip for 15 consecutive days. The device should not be worn during bathing or swimming. Data from the first day and any day with \<12 hours of wear time will be excluded. A valid dataset requires at least two weekdays and two weekend days of usable data.
5. Body Composition
Body composition will be measured using the following techniques:
Magnetic Resonance Imaging (MRI; Philips Multiva 1.5T) Dual-energy X-ray Absorptiometry (DXA; HOLOGIC Horizon Wi, USA) Bioelectrical Impedance Analysis (BIA; TANITA MC-980, Japan) Parameters to be assessed include total and regional fat mass, lean mass, and fat percentage across the limbs and trunk. MRI will be used for whole-body fat distribution analysis by trained technicians.
6. Mental Health Assessment The Symptom Checklist-90 (SCL-90) will be used to evaluate psychological well-being. This tool measures ten dimensions: somatization, obsessive-compulsive traits, interpersonal sensitivity, depression, anxiety, hostility, phobia, paranoid ideation, psychosis, and additional symptoms. Scores for each dimension and overall symptom severity will be calculated.
7. Food Intake and Hunger Assessment Meals will be designed based on the energy distribution guidelines from the Chinese Dietary Guidelines. After a standardized lunch, participants will receive a test meal (packaging removed) containing predefined macronutrient and energy levels five hours later. Food intake will be ad libitum, and hunger levels will be assessed based on behavioral indicators. Blood samples (4 mL) will be collected at baseline (pre-dinner), and 15, 30, and 60 minutes post-dinner for appetite-related hormones analysis such as ghrelin and PYY.
8. Sleep Quality Monitoring Sleep will be monitored using the Heartcare Youhu Pro AI Precision Health Management System, which tracks total sleep duration, sleep efficiency, cycle durations, heart rate, and respiratory patterns. These metrics will be used to assess sleep quality.
9. Cognitive Function Assessment
Cognitive performance will be evaluated using:
Mini-Mental State Examination (MMSE): Assesses orientation, memory, attention, language, and visuospatial function. Scores of 25-30 indicate normal function; 20-24 mild, 10-19 moderate, and \<10 severe cognitive impairment.
Montreal Cognitive Assessment (MoCA): Screens for impairment across eight cognitive domains. A score ≥26 is considered normal.
10. Non-Invasive Brain Function Monitoring Functional Near-Infrared Spectroscopy (fNIRS) will be used to assess brain activity by measuring changes in oxyhemoglobin and deoxyhemoglobin concentrations. We may use the BS2000 near-infrared imaging system for this purpose.
Assessment Areas: Prefrontal cortex, motor cortex, frontal pole, dorsolateral prefrontal cortex, primary motor/somatosensory cortex, premotor and supplementary motor cortex-on both healthy and affected sides.
Key Indicators:HbO, HbR, and HbT concentration changes during a 0-40 sec task window. 3D topological maps (HbO beta values). Activation levels at rest. Functional connectivity (HbO).
11. Gait Analysis Laboratory
A 3D markerless motion capture system (Xiangneng-Dongxi) will be used for gait analysis. This non-invasive system captures:
Spatiotemporal Parameters: Step time, frequency, speed, stride length/width, and symmetry Kinematic Parameters: Joint angles (pelvis, hip, knee), motion curves, ground reaction forces, and joint torques
12. Gut Microbiota and Blood Metabolomics Mid-portion fecal samples and 5 mL blood samples will be collected. Fecal samples will undergo non-targeted microbiome analysis at Novogene, while blood samples will be analyzed at Biotree Bioscience for metabolomic profiling, including appetite-related hormones such as ghrelin and PYY.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
rehabilitation
Individuals aged 20 to 70 years, who are recovering from stroke or motor injuries
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Rehabilitation patients with stroke or motor injuries;
Exclusion Criteria
* Loss of consciousness;
* Individuals with metallic implants (e.g., pacemakers);
* Severe metabolic diseases (e.g., diabetes, other hereditary metabolic disorders);
* Patients with claustrophobia;
* Individuals with anorexia nervosa;
* Women in the preconception period, pregnancy, or lactation;
* Uremic patients;
* Inability to lie flat for one hour.
20 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xueying Zhang
Principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xueying Zhang, PhD
Role: PRINCIPAL_INVESTIGATOR
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
John R Speakman, PhD
Role: PRINCIPAL_INVESTIGATOR
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangdong Jianxiang Hospital Group
Foshan, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Speakman JR, Yamada Y, Sagayama H, Berman ESF, Ainslie PN, Andersen LF, Anderson LJ, Arab L, Baddou I, Bedu-Addo K, Blaak EE, Blanc S, Bonomi AG, Bouten CVC, Bovet P, Buchowski MS, Butte NF, Camps SGJA, Close GL, Cooper JA, Creasy SA, Das SK, Cooper R, Dugas LR, Ebbeling CB, Ekelund U, Entringer S, Forrester T, Fudge BW, Goris AH, Gurven M, Hambly C, El Hamdouchi A, Hoos MB, Hu S, Joonas N, Joosen AM, Katzmarzyk P, Kempen KP, Kimura M, Kraus WE, Kushner RF, Lambert EV, Leonard WR, Lessan N, Ludwig DS, Martin CK, Medin AC, Meijer EP, Morehen JC, Morton JP, Neuhouser ML, Nicklas TA, Ojiambo RM, Pietilainen KH, Pitsiladis YP, Plange-Rhule J, Plasqui G, Prentice RL, Rabinovich RA, Racette SB, Raichlen DA, Ravussin E, Reynolds RM, Roberts SB, Schuit AJ, Sjodin AM, Stice E, Urlacher SS, Valenti G, Van Etten LM, Van Mil EA, Wells JCK, Wilson G, Wood BM, Yanovski J, Yoshida T, Zhang X, Murphy-Alford AJ, Loechl CU, Melanson EL, Luke AH, Pontzer H, Rood J, Schoeller DA, Westerterp KR, Wong WW; IAEA DLW database group. A standard calculation methodology for human doubly labeled water studies. Cell Rep Med. 2021 Feb 16;2(2):100203. doi: 10.1016/j.xcrm.2021.100203. eCollection 2021 Feb 16.
WEIR JB. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol. 1949 Aug;109(1-2):1-9. doi: 10.1113/jphysiol.1949.sp004363. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SIAT-IRB-250615-H0986
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.